Glatiramer Acetate (Copaxone®)

( DrugBank: Glatiramer / KEGG DRUG: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	4

告示番号	疾患名（ページ内リンク）	臨床試験数
156	レット症候群	1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01489254 (ClinicalTrials.gov)	October 2011	8/12/2011	Efficacy and Safety of GTR in Comparison to Copaxone®	Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Tri ...	Multiple Sclerosis	Drug: Glatiramer Acetate (GTR);Drug: Glatiramer Acetate (Copaxone®);Drug: Placebo	Synthon BV	NULL	Completed	18 Years	55 Years	All	794	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany ...
2	NCT00398528 (ClinicalTrials.gov)	September 2006	9/11/2006	An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Rela ...	An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From G ...	Relapsing-Remitting Multiple Sclerosis	Drug: Glatiramer acetate, (Copaxone®);Drug: IFN-ß-1a, (Avonex®)	Neurognostics	NULL	Terminated	18 Years	65 Years	Both	48		United States
3	NCT00101959 (ClinicalTrials.gov)	November 2004	18/1/2005	Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Scler ...	An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Trea ...	Relapsing-Remitting Multiple Sclerosis	Drug: Rebif	EMD Serono	NULL	Withdrawn	18 Years	60 Years	Both	0	Phase 4	United States
4	NCT00203021 (ClinicalTrials.gov)	March 26, 1994	12/9/2005	Glatiramer Acetate (Copaxone®)Study to Follow Participants From the First Original Study for Safety ...	Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease ...	Relapsing-Remitting Multiple Sclerosis	Drug: Glatiramer acetate	Teva Branded Pharmaceutical Products R&D, Inc.	NULL	Completed	18 Years	N/A	All	208	Phase 4	United States

First Previous1Next Last

156. レット症候群

臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02023424 (ClinicalTrials.gov)	January 2014	23/12/2013	An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetateon Girls W ...	An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate(Copaxone ...	Rett Syndrome	Drug: Glatiramer Acetate (Copaxone®)	Sheba Medical Center	NULL	Recruiting	6 Years	15 Years	Female	10	Phase 1	Israel

First Previous1Next Last